Pharmaceutical Market Research Company in Ireland

For pharmaceutical and life-sciences decisions in the Irish market, BioNixus is a leading specialist: NCPE-aligned study design, HSE reimbursement and IPHA framework agreement payer context, HCP and KOL recruitment across major Irish academic medical centres, and outputs built for launch, market access, and lifecycle management teams.

Pharmaceutical market research in Ireland is evidence generation for drug launch, market access, and lifecycle decisions across HPRA, NCPE, IPHA, and HSE reimbursement contexts. BioNixus focuses on physician behavior, payer and reimbursement dynamics, and institution-level adoption so commercial and access teams can prioritize Irish market execution across oncology, immunology, cardiovascular, and rare disease therapy areas.

The IPHA (Irish Pharmaceutical Healthcare Association) framework agreement governs pricing and supply arrangements between industry and the State, shaping the price referencing and cost dynamics that feed into HSE reimbursement decisions. This has meaningfully shaped commercial strategy for new product launches, particularly in oncology and rare disease. BioNixus conducts framework agreement impact research: payer and reimbursement strategy studies, HCP pricing perception research, and commercial team intelligence on how the IPHA agreement affects market access dynamics in Ireland.

BioNixus covers all major Irish payer and reimbursement mechanisms: the HSE (Health Service Executive) as the single national public healthcare payer, reimbursement pathways including the GMS (General Medical Services) scheme, the Drug Payment Scheme (DPS), and the High Tech Drug Scheme, alongside NCPE cost-effectiveness assessment and IPHA framework agreement pricing negotiations. Research includes in-depth interviews with HSE reimbursement decision makers, NCPE assessment stakeholders, and hospital drugs and therapeutics committee members.

Yes. BioNixus designs and executes Irish HCP research in compliance with Research Ethics Committee (REC) requirements and GDPR data privacy standards, given Ireland's status as an EU member state. For studies requiring ethics review, BioNixus supports protocol development and ethics documentation, and accounts for HIQA (Health Information and Quality Authority) standards oversight where relevant to health and social care settings. All Irish respondent recruitment is consent-based with documented data handling procedures.

Scope drives cost: a focused Irish physician quantitative survey often starts in the low-to-mid five figures EUR; full mixed-method access programs with HSE reimbursement mapping and KOL depth interviews are higher. BioNixus scopes programs to one decision per phase so sponsors avoid unfocused fieldwork spend. The Irish market requires verified HCP recruitment and REC-compliant, GDPR-aligned protocols — which reflects in project pricing.

BioNixus recruits from major Irish academic medical centres and teaching hospitals including Beaumont Hospital, St James's Hospital, and affiliated centres linked to Trinity College Dublin, University College Dublin, and RCSI (Royal College of Surgeons in Ireland), as well as community practice networks across the HSE's national structure. For specialty areas such as oncology or rare disease, we extend recruitment to national specialty referral centres.

Yes. Irish modules can run standalone or with comparable cells in the UK, USA, Germany, France, Canada, Saudi Arabia, or UAE using consistent instruments — enabling global portfolio committees to benchmark Irish market dynamics against international markets with one research partner.